| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
144,770,000 |
| Market
Cap: |
550.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.335 - $8.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptive Biotechnologies is a commercial-stage company developing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s immune medicine platform applies its main technologies to read the genetic code of a patient's immune system. Co.'s clinical diagnostic product, clonoSEQ, is authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
181,388 |
181,647 |
370,810 |
539,321 |
| Total Sell Value |
$624,469 |
$625,539 |
$2,103,520 |
$3,574,731 |
| Total People Sold |
8 |
8 |
9 |
11 |
| Total Sell Transactions |
8 |
9 |
13 |
36 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baldo Lance |
Chief Medical Officer |
• – – |
2022-03-08 |
4 |
AS |
$11.43 |
$38,291 |
D/D |
(3,350) |
17,171 |
|
-24% |
|
| Taylor Stacy L |
SVP and General Counsel |
• – – |
2022-03-08 |
4 |
AS |
$11.44 |
$27,307 |
D/D |
(2,387) |
72,859 |
|
-24% |
|
| Lo Francis |
Chief People Officer |
• – – |
2022-03-08 |
4 |
AS |
$11.44 |
$40,978 |
D/D |
(3,582) |
89,588 |
|
-24% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-08 |
4 |
AS |
$11.38 |
$168,595 |
D/D |
(14,815) |
1,916,154 |
|
-24% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-08 |
4 |
OE |
$6.32 |
$93,631 |
D/D |
14,815 |
1,930,969 |
|
- |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-07 |
4 |
AS |
$11.53 |
$171,162 |
D/D |
(14,815) |
1,916,154 |
|
-19% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-07 |
4 |
OE |
$6.32 |
$93,631 |
D/D |
14,815 |
1,930,969 |
|
- |
|
| Rubinstein Julie |
President |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$55,402 |
D/D |
(4,613) |
226,513 |
|
19% |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$54,249 |
D/D |
(4,517) |
311,960 |
|
19% |
|
| Benzeno Sharon |
Chief Business Development Off |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$32,067 |
D/D |
(2,670) |
102,596 |
|
19% |
|
| Baldo Lance |
Chief Medical Officer |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$28,500 |
D/D |
(2,373) |
20,521 |
|
19% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$14,940 |
D/D |
(1,244) |
123,724 |
|
19% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-07 |
4 |
S |
$12.01 |
$53,132 |
D/D |
(4,424) |
1,916,154 |
|
19% |
|
| Piskel Kyle |
Principal Accounting Officer |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$2,642 |
D/D |
(220) |
47,665 |
|
19% |
|
| Lo Francis |
Chief People Officer |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$18,844 |
D/D |
(1,569) |
93,170 |
|
19% |
|
| Taylor Stacy L |
SVP and General Counsel |
• – – |
2022-03-07 |
4 |
S |
$12.01 |
$18,844 |
D/D |
(1,569) |
75,246 |
|
19% |
|
| Rubinstein Julie |
President |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
185,338 |
231,126 |
|
- |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
247,117 |
316,477 |
|
- |
|
| Benzeno Sharon |
Chief Business Development Off |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
82,372 |
105,266 |
|
- |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
74,135 |
124,968 |
|
- |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
247,117 |
1,920,578 |
|
- |
|
| Piskel Kyle |
Principal Accounting Officer |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
41,186 |
47,885 |
|
- |
|
| Lo Francis |
Chief People Officer |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
74,135 |
94,739 |
|
- |
|
| Sood Nitin |
Chief Commercial Officer |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
65,898 |
163,111 |
|
- |
|
| Taylor Stacy L |
SVP and General Counsel |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
61,779 |
76,815 |
|
- |
|
867 Records found
|
|
Page 4 of 35 |
|
|
0.30 (8.57%) 
